title: Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.
abstract: The finding that human factor VIII (fVIII) inhibitor antibodies with C2 domain epitopes interfere with the binding of fVIII to phosphatidylserine (PS) suggested that this is the mechanism by which they inactivate fVIII. We constructed a recombinant C2 domain polypeptide and demonstrated that it bound to all six human inhibitors with fVIII light chain specificity. Thus, some antibodies within the polyclonal anti-light chain population require only amino acids within C2 for binding. Recombinant C2 also partially or completely neutralized the inhibitor titer of these plasmas, demonstrating that anti-C2 antibodies inhibit fVIII activity. Immunoblotting of a series of C2 deletion polypeptides, expressed in Escherichia coli, with inhibitor plasmas showed that the epitopes for human inhibitors consist of a common core of amino acid residues 2248 through 2312 with differing extensions for individual inhibitors. The epitope of inhibitory monoclonal antibody (MoAb) ESH8 was localized to residues 2248 through 2285. Three human antibodies and anti-C2 MoAb NMC-VIII/5 bound to a synthetic peptide consisting of amino acids 2303 through 2332, a PS-binding site, but MoAb ESH8 did not. These antibodies also inhibited the binding of fVIII to synthetic phospholipid membranes of PS and phosphatidylcholine, confirming that the blocked epitopes contribute to membrane binding as well as binding to PS. In contrast, MoAb ESH8 did not inhibit binding. As the maximal function of activated fVIII in the intrinsic factor Xase complex requires its binding to a phospholipid membrane, we propose that fVIII inhibition by anti-C2 antibodies is related to the overlap of their epitopes with the PS-binding site. MoAb ESH8 did not inhibit fVIII binding to PS-containing membranes, suggesting the existence of a second mechanism of fVIII inhibition by anti-C2 antibodies.
authors.affiliation: Holland Laboratory, American Red Cross, Rockville, MD 20855, USA.
authors.forename: D
authors.initials: D
authors.lastname: Scandella
authors.forename: G E
authors.initials: GE
authors.lastname: Gilbert
authors.forename: M
authors.initials: M
authors.lastname: Shima
authors.forename: H
authors.initials: H
authors.lastname: Nakai
authors.forename: C
authors.initials: C
authors.lastname: Eagleson
authors.forename: M
authors.initials: M
authors.lastname: Felch
authors.forename: R
authors.initials: R
authors.lastname: Prescott
authors.forename: K J
authors.initials: KJ
authors.lastname: Rajalakshmi
authors.forename: L W
authors.initials: LW
authors.lastname: Hoyer
authors.forename: E
authors.initials: E
authors.lastname: Saenko
mesh_terms: D000595:Amino Acid Sequence; D000906:Antibodies / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000918:Antibody Specificity; D001667:Binding, Competitive; D003001:Cloning, Molecular; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000032:analysis*; D004926:Escherichia coli; D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000276:immunology*; D005434:Flow Cytometry; D006801:Humans; D015151:Immunoblotting; D007074:Immunoglobulin G / Q000494:pharmacology; D007700:Kinetics; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000032:analysis / Q000276:immunology*; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D000939:Epitopes; D007074:Immunoglobulin G; D010446:Peptide Fragments; D011994:Recombinant Proteins; D005169:Factor VIII